Alpha Tau Medical Stock (NASDAQ:DRTS)


ForecastOwnershipChart

Previous Close

$4.23

52W Range

$2.14 - $4.69

50D Avg

$3.84

200D Avg

$3.21

Market Cap

$353.78M

Avg Vol (3M)

$63.23K

Beta

1.07

Div Yield

-

DRTS Company Profile


Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

125

IPO Date

Mar 08, 2021

Website

DRTS Performance


Peer Comparison


TickerCompany
AARDAardvark Therapeutics, Inc. Common Stock
CTNMContineum Therapeutics, Inc. Class A Common Stock
BLRXBioLineRx Ltd.
CADLCandel Therapeutics, Inc.
GALTGalectin Therapeutics Inc.
LRMRLarimar Therapeutics, Inc.
DMACDiaMedica Therapeutics Inc.
REPLReplimune Group, Inc.
ALDXAldeyra Therapeutics, Inc.
IMMPImmutep Limited